Effects of escitalopram on stress-related relapses in women with multiple sclerosis: An open-label, randomized, controlled, one-year follow-up study

European Neuropsychopharmacology

Volumn 20, Issue 2, 2010, Pages 123-131

  Mitsonis, Charalampos I ^a   Zervas, Iannis M ^a   Potagas, Constantin M ^a   Mitropoulos, Panagiotis A ^b   Dimopoulos, Nikolaos P ^c   Sfagos, Constantin A ^a   Papadimitriou, George N ^a   Vassilopoulos, Demetrios C ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

^c Athens Psychiatric Hospital Dromokaition   (Greece)

Author keywords

Escitalopram; Multiple sclerosis; Relapse; Stress; Stressful life events

Indexed keywords

ESCITALOPRAM;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LIFE STRESS; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RELAPSE; RISK FACTOR; XEROSTOMIA;

ADOLESCENT; ADULT; CITALOPRAM; FEMALE; HUMANS; LIFE CHANGE EVENTS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECURRENCE; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 73249120990     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2009.10.004     Document Type: Article

References (55)

1. Abumaria N., Rygula R., Hiemke C., Fuchs E., Havemann-Reinecke U., Rüther E., and Flügge G. Effect of chronic citalopram on serotonin related and stress-regulated genes in the dorsal raphe nucleus of the rat. Eur. Neuropsychopharmacol. 17 (2007) 417-429
2. Ackerman K.D., Heyman R., Rabin B.S., Anderson B.P., Houck P.R., Frank E., and Baum A. Stressful life events precede exacerbations of multiple sclerosis. Psychosom. Med. 64 (2002) 916-920
3. Aguilera G. Regulation of pituitary ACTH secretion during chronic stress. Front. Neuroendocrinol. 15 (1994) 321-350
4. Allgulander C., Florea I., and Huusom A.K. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int. J. Neuropsychopharmacol. 9 (2006) 495-505
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental disorders, Text Revision (DSM-IV-TR). Fourth ed. (2000), American Psychiatric Association, Washington DC
6. Anisman H., Zaharia M.D., Meaney M.J., and Merali Z. Do early-life events permanently alter behavioral and hormonal responses to stressors?. Int. J. Dev. Neurosci. 16 (1998) 149-164
7. Arborelius L., Owens M.J., Plotsky P.M., and Nemeroff C.B. The role of corticotropin-releasing factor in depression and anxiety disorders. J. Endocrinol. 160 (1999) 1-12
8. Avitsur R., Stark J.L., and Sheridan J.F. Social stress induces glucocorticoid resistance in subordinate animals. Horm. Behav. 39 (2001) 247-257
9. Barden N., Reul J.M., and Holsboer F. Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system?. Trends Neurosci. 18 (1995) 6-11
10. Brown G.W. Life events and measurement. In: Brown G.W., and Harris T.O. (Eds). Life Events and Illness (1989), Guildford, New York 3-45
11. Brown R.F., Tennant C.C., Dunn S.M., and Pollard J.D. A review of stress-relapse interactions in multiple sclerosis: important features and stress-mediating and -moderating variables. Mult. Scler. 11 (2005) 477-484
12. Brown R.F., Tennant C.C., Sharrock M., Hodgkinson S., Dunn S.M., and Pollard J.D. Relationship between stress and relapse in multiple sclerosis: part I. Important features. Mult. Scler. 12 (2006) 453-464
13. Brown R.F., Tennant C.C., Sharrock M., Hodgkinson S., Dunn S.M., and Pollard J.D. Relationship between stress and relapse in multiple sclerosis: part II. Direct and indirect relationships. Mult. Scler. 12 (2006) 465-475
14. Buljevac D., Flach H.Z., Hop W.C., Hijdra D., Laman J.D., Savelkoul H.F., van Der Meché F.G., van Doorn P.A., and Hintzen R.Q. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 125 (2002) 952-960
15. Buljevac D., Hop W.C., Reedeker W., Janssens A.C., van der Meché F.G., van Doorn P.A., and Hintzen R.Q. Self reported stressful life events and exacerbations in multiple sclerosis: prospective study. BMJ 327 (2003) 646
16. Chaouloff F. Serotonin, stress and corticoids. J. Psychopharmacol. 14 (2000) 139-151
17. Confavreux C., Hutchinson M., Hours M.M., Cortinovis-Tourniaire P., and Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N. Engl. J. Med. 339 (1998) 285-291
18. Courtney A.M., Treadaway K., Remington G., and Frohman E. Multiple sclerosis. Med. Clin. North Am. 93 (2009) 451-476
19. Fineberg N.A., Tonnoir B., Lemming O., and Stein D.J. Escitalopram prevents relapse of obsessive-compulsive disorder. Eur. Neuropsychopharmacol. 17 (2007) 430-439
20. Heesen C., Gold S.M., Huitinga I., and Reul J.M. Stress and hypothalamic-pituitary-adrenal axis function in experimental autoimmune encephalomyelitis and multiple sclerosis - a review. Psychoneuroendocrinology 32 (2007) 604-618
21. Héry M., Sémont A., Fache M.P., Faudon M., and Héry F. The effects of serotonin on glucocorticoid receptor binding in rat raphe nuclei and hippocampal cells in culture. J. Neurochem. 74 (2000) 406-413
22. Hesketh S., Jessop D.S., Hogg S., and Harbuz M.S. Differential actions of acute and chronic citalopram on the rodent hypothalamic-pituitary-adrenal axis response to acute restraint stress. J. Endocrinol. 185 (2005) 373-382
23. Hirschfeld R.M., and Vornik L.A. Newer antidepressants: review of efficacy and safety of escitalopram and duloxetine. J. Clin. Psychiatry 65 (2004) 46-52
24. Jensen J.B., Jessop D.S., Harbuz M.S., Mørk A., Sánchez C., and Mikkelsen J.D. Acute and long-term treatments with the selective serotonin reuptake inhibitor citalopram modulate the HPA axis activity at different levels in male rats. J. Neuroendocrinol. 11 (1999) 465-471
25. Kong E.K., Peng L., Chen Y., Yu A.C., and Hertz L. Up-regulation of 5-HT2B receptor density and receptor-mediated glycogenolysis in mouse astrocytes by long-term fluoxetine administration. Neurochem. Res. 27 (2002) 113-120
26. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 (1983) 1444-1452
27. Li Q., Muma N.A., Battaglia G., and Van de Kar L.D. A desensitization of hypothalamic 5-HT1A receptors by repeated injections of paroxetine: reduction in the levels of G(i) and G(o) proteins and neuroendocrine responses, but not in the density of 5-HT1A receptors. J. Pharmacol. Exp. Ther. 282 (1997) 1581-1590
28. Lowry C.A. Functional subsets of serotonergic neurones: implications for control of the hypothalamic-pituitary-adrenal axis. J. Neuroendocrinol. 14 (2002) 911-923
29. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., McFarland H.F., Paty D.W., Polman C.H., Reingold S.C., Sandberg-Wollheim M., Sibley W., Thompson A., van den Noort S., Weinshenker B.Y., and Wolinsky J.S. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 50 (2001) 121-127
30. Mitsonis C.I., Zervas I.M., Mitropoulos P.A., Dimopoulos N.P., Soldatos C.R., Potagas C.M., and Sfagos C.A. The impact of stressful life events on risk of relapse in women with multiple sclerosis: a prospective study. Eur. Psychiatr. 23 (2008) 497-504
31. Mitsonis C., Potagas C., Zervas I., and Sfagos K. The effects of stressful life events on the course of multiple sclerosis: a review. Int. J. Neurosci. 119 (2009) 315-335
32. Mohr D.C., and Pelletier D. A temporal framework for understanding the effects of stressful life events on inflammation in patients with multiple sclerosis. Brain Behav. Immun. 20 (2006) 27-36
33. Mohr D.C., Goodkin D.E., Bacchetti P., Boudewyn A.C., Huang L., Marrietta P., Cheuk W., and Dee B. Psychological stress and the subsequent appearance of new brain MRI lesions in MS. Neurology 55 (2000) 55-61
34. Moncek F., Duncko R., and Jezova D. Repeated citalopram treatment but not stress exposure attenuates hypothalamic-pituitary-adrenocortical axis response to acute citalopram injection. Life Sci. 72 (2003) 1353-1365
35. Mostert J.P., Sijens P.E., Oudkerk M., and De Keyser J. Fluoxetine increases cerebral white matter NAA/Cr ratio in patients with multiple sclerosis. Neurosci. Lett. 402 (2006) 22-24
36. Mostert J.P., Koch M.W., Heerings M., Heersema D.J., and De Keyser J. Therapeutic potential of fluoxetine in neurological disorders. CNS Neurosci. Ther. 14 (2008) 153-164
37. Mostert J.P., Admiraal-Behloul F., Hoogduin J.M., Luyendijk J., Heersema D.J., van Buchem M.A., and De Keyser J. Effects of fluoxetine on disease activity in relapsing multiple sclerosis: a double-blind, placebo-controlled, exploratory study. J. Neurol. Neurosurg. Psychiatry 79 (2008) 1027-1031
38. Nickel T., Sonntag A., Schill J., Zobel A.W., Ackl N., Brunnauer A., Murck H., Ising M., Yassouridis A., Steiger A., Zihl J., and Holsboer F. Clinical and neurobiological effects of tianeptine and paroxetine in major depression. J. Clin. Psychopharmacol. 23 (2003) 155-168
39. Nikisch G., Mathé A.A., Czernik A., Thiele J., Bohner J., Eap C.B., Agren H., and Baumann P. Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response. Psychopharmacology 181 (2005) 751-760
40. Nikisch G., Agren H., Eap C.B., Czernik A., Baumann P., and Mathé A.A. Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram. Int. J. Neuropsychopharmacol. 8 (2005) 403-410
41. Owens M.J., Morgan W.N., Plott S.J., and Nemeroff C.B. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J. Pharmacol. Exp. Ther. 283 (1997) 1305-1322
42. Pae C.U., Masand P.S., Peindl K., Mannelli P., Han C., Marks D.M., and Patkar A.A. An open-label, rater-blinded, flexible-dose, 8-week trial of escitalopram in patients with major depressive disorder with atypical features. Prim. Care Companion J. Clin. Psychiat. 10 (2008) 205-210
43. Pariante C.M., and Miller A.H. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol. Psychiatry 49 (2001) 391-404
44. Philippopoulos G.S., Wittkower E.D., and Cousineau A. The etiologic significance of emotional factors in onset and exacerbations of multiple sclerosis; a preliminary report. Psychosom. Med. 20 (1958) 458-474
45. Potagas C., Mitsonis C., Watier L., Dellatolas G., Retziou A., Mitropoulos P., Sfagos C., and Vassilopoulos D. Influence of anxiety and reported stressful life events on relapses in multiple sclerosis: a prospective study. Mult. Scler. 14 (2008) 1262-1268
46. Sánchez C., Gruca P., and Papp M. R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model. Behav. Pharmacol. 14 (2003) 465-470
47. Schüle C. Neuroendocrinological mechanisms of actions of antidepressant drugs. J. Neuroendocrinol. 19 (2007) 213-226
48. Schwartz C.E., Foley F.W., Rao S.M., Bernardin L.J., Lee H., and Genderson M.W. Stress and course of disease in multiple sclerosis. Behav. Med. 25 (1999) 110-116
49. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., and Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 59 (1998) 22-33
50. Sibley W.A. Risk factors in multiple sclerosis. In: Raine C.S., McFarland H.F., and Tourtelotte W.W. (Eds). Multiple Sclerosis: Clinical and Pathogenetic Basis (1997), Chapman & Hall, London 141-148
51. Sijens P.E., Mostert J.P., Irwan R., Potze J.H., Oudkerk M., and De Keyser J. Impact of fluoxetine on the human brain in multiple sclerosis as quantified by proton magnetic resonance spectroscopy and diffusion tensor imaging. Psychiatry Res. 164 (2008) 274-282
52. Stadelmann C., Kerschensteiner M., Misgeld T., Brück W., Hohlfeld R., and Lassmann H. BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells?. Brain 125 (2002) 75-85
53. Stout S.C., Owens M.J., and Nemeroff C.B. Regulation of corticotropin-releasing factor neuronal systems and hypothalamic-pituitary-adrenal axis activity by stress and chronic antidepressant treatment. J. Pharmacol. Exp. Ther. 300 (2002) 1085-1092
54. Stys P.K. General mechanisms of axonal damage and its prevention. J. Neurol. Sci. 233 (2005) 3-13
55. Uys J.D., Muller C.J., Marais L., Harvey B.H., Stein D.J., and Daniels W.M. Early life trauma decreases glucocorticoid receptors in rat dentate gyrus upon adult re-stress: reversal by escitalopram. Neuroscience 137 (2006) 619-625